Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells

Roberta Bosotti, Patrizia Carpinelli, Sandra Healy, Giuseppe Locatelli, Paolo Cappella, Luisa Lanfrancone, Raffaele Calogero, Jurgen Moll, Antonella Isacchi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aurora kinases represent an appealing target for anticancer therapies and several Aurora inhibitors are in clinical development, including the potent pan-Aurora inhibitor Danusertib. Treatment with Aurora inhibitors has been shown to induce diverse biological responses in different tumor cells, in part depending on TP53 status. To characterize the effects of Danusertib at the transcriptional level we carried out gene expression profiling of wt and TP53 mutant tumor cells showing differential cell cycle response upon drug treatment. We found that treatment with Danusertib induces a strong transcriptional response only in TP53 wt cells, with an overlapping pattern of expression of TP53-dependent genes among the three cell lines tested, while a prevalent signature could not be identified in the two TP53 mutant cells, suggesting that TP53 status is a key determinant for the observed transcriptional effects. This work led to the identification of a number of genes consistently modulated by Aurora treatment in TP53 cells. One of these is GDF15, a secreted protein belonging to the TGF-β superfamily, for which we found a potential role in resistance to Danusertib, and which could represent a potential biomarker for Danusertib treatment in TP53 WT tumors and in surrogate tissues such as blood or skin.

Original languageEnglish
Pages (from-to)202-208
Number of pages7
JournalGene
Volume494
Issue number2
DOIs
Publication statusPublished - Feb 25 2012

Fingerprint

Biomarkers
Aurora Kinases
Neoplasms
p53 Genes
Gene Expression Profiling
Cell Cycle
danusertib
Cell Line
Skin
Pharmaceutical Preparations
Genes
Proteins
Therapeutics

Keywords

  • Aurora kinase inhibitor
  • Biomarker
  • Danusertib
  • Transcription

ASJC Scopus subject areas

  • Genetics

Cite this

Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells. / Bosotti, Roberta; Carpinelli, Patrizia; Healy, Sandra; Locatelli, Giuseppe; Cappella, Paolo; Lanfrancone, Luisa; Calogero, Raffaele; Moll, Jurgen; Isacchi, Antonella.

In: Gene, Vol. 494, No. 2, 25.02.2012, p. 202-208.

Research output: Contribution to journalArticle

Bosotti, R, Carpinelli, P, Healy, S, Locatelli, G, Cappella, P, Lanfrancone, L, Calogero, R, Moll, J & Isacchi, A 2012, 'Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells', Gene, vol. 494, no. 2, pp. 202-208. https://doi.org/10.1016/j.gene.2011.08.014
Bosotti, Roberta ; Carpinelli, Patrizia ; Healy, Sandra ; Locatelli, Giuseppe ; Cappella, Paolo ; Lanfrancone, Luisa ; Calogero, Raffaele ; Moll, Jurgen ; Isacchi, Antonella. / Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells. In: Gene. 2012 ; Vol. 494, No. 2. pp. 202-208.
@article{653aa06104394ebb87c16b765dc5a9b0,
title = "Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells",
abstract = "Aurora kinases represent an appealing target for anticancer therapies and several Aurora inhibitors are in clinical development, including the potent pan-Aurora inhibitor Danusertib. Treatment with Aurora inhibitors has been shown to induce diverse biological responses in different tumor cells, in part depending on TP53 status. To characterize the effects of Danusertib at the transcriptional level we carried out gene expression profiling of wt and TP53 mutant tumor cells showing differential cell cycle response upon drug treatment. We found that treatment with Danusertib induces a strong transcriptional response only in TP53 wt cells, with an overlapping pattern of expression of TP53-dependent genes among the three cell lines tested, while a prevalent signature could not be identified in the two TP53 mutant cells, suggesting that TP53 status is a key determinant for the observed transcriptional effects. This work led to the identification of a number of genes consistently modulated by Aurora treatment in TP53 cells. One of these is GDF15, a secreted protein belonging to the TGF-β superfamily, for which we found a potential role in resistance to Danusertib, and which could represent a potential biomarker for Danusertib treatment in TP53 WT tumors and in surrogate tissues such as blood or skin.",
keywords = "Aurora kinase inhibitor, Biomarker, Danusertib, Transcription",
author = "Roberta Bosotti and Patrizia Carpinelli and Sandra Healy and Giuseppe Locatelli and Paolo Cappella and Luisa Lanfrancone and Raffaele Calogero and Jurgen Moll and Antonella Isacchi",
year = "2012",
month = "2",
day = "25",
doi = "10.1016/j.gene.2011.08.014",
language = "English",
volume = "494",
pages = "202--208",
journal = "Gene",
issn = "0378-1119",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells

AU - Bosotti, Roberta

AU - Carpinelli, Patrizia

AU - Healy, Sandra

AU - Locatelli, Giuseppe

AU - Cappella, Paolo

AU - Lanfrancone, Luisa

AU - Calogero, Raffaele

AU - Moll, Jurgen

AU - Isacchi, Antonella

PY - 2012/2/25

Y1 - 2012/2/25

N2 - Aurora kinases represent an appealing target for anticancer therapies and several Aurora inhibitors are in clinical development, including the potent pan-Aurora inhibitor Danusertib. Treatment with Aurora inhibitors has been shown to induce diverse biological responses in different tumor cells, in part depending on TP53 status. To characterize the effects of Danusertib at the transcriptional level we carried out gene expression profiling of wt and TP53 mutant tumor cells showing differential cell cycle response upon drug treatment. We found that treatment with Danusertib induces a strong transcriptional response only in TP53 wt cells, with an overlapping pattern of expression of TP53-dependent genes among the three cell lines tested, while a prevalent signature could not be identified in the two TP53 mutant cells, suggesting that TP53 status is a key determinant for the observed transcriptional effects. This work led to the identification of a number of genes consistently modulated by Aurora treatment in TP53 cells. One of these is GDF15, a secreted protein belonging to the TGF-β superfamily, for which we found a potential role in resistance to Danusertib, and which could represent a potential biomarker for Danusertib treatment in TP53 WT tumors and in surrogate tissues such as blood or skin.

AB - Aurora kinases represent an appealing target for anticancer therapies and several Aurora inhibitors are in clinical development, including the potent pan-Aurora inhibitor Danusertib. Treatment with Aurora inhibitors has been shown to induce diverse biological responses in different tumor cells, in part depending on TP53 status. To characterize the effects of Danusertib at the transcriptional level we carried out gene expression profiling of wt and TP53 mutant tumor cells showing differential cell cycle response upon drug treatment. We found that treatment with Danusertib induces a strong transcriptional response only in TP53 wt cells, with an overlapping pattern of expression of TP53-dependent genes among the three cell lines tested, while a prevalent signature could not be identified in the two TP53 mutant cells, suggesting that TP53 status is a key determinant for the observed transcriptional effects. This work led to the identification of a number of genes consistently modulated by Aurora treatment in TP53 cells. One of these is GDF15, a secreted protein belonging to the TGF-β superfamily, for which we found a potential role in resistance to Danusertib, and which could represent a potential biomarker for Danusertib treatment in TP53 WT tumors and in surrogate tissues such as blood or skin.

KW - Aurora kinase inhibitor

KW - Biomarker

KW - Danusertib

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=84856320049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856320049&partnerID=8YFLogxK

U2 - 10.1016/j.gene.2011.08.014

DO - 10.1016/j.gene.2011.08.014

M3 - Article

VL - 494

SP - 202

EP - 208

JO - Gene

JF - Gene

SN - 0378-1119

IS - 2

ER -